{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:49:12Z","timestamp":1790315352933,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cct.2013.06.012","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T03:00:42Z","timestamp":1372474842000},"page":"616-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Personalized medicine in Alzheimer's disease and depression"],"prefix":"10.1016","volume":"36","author":[{"given":"Tatiana","family":"Souslova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa C.","family":"Marple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Spiekerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin A","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2013.06.012_bb0005","series-title":"Neuroscience of clinical psychiatry: the pathophysiology of behavior and mental illness","author":"Higgins","year":"2007"},{"key":"10.1016\/j.cct.2013.06.012_bb0010","series-title":"The global economic burden of non-communicable diseases","author":"Bloom","year":"2011"},{"key":"10.1016\/j.cct.2013.06.012_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.ajp.2011.11010050","article-title":"DSM-5: how reliable is reliable enough?","volume":"169","author":"Kraemer","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0025","unstructured":"International Classification of Diseases-10 Chapter 5. Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization."},{"key":"10.1016\/j.cct.2013.06.012_bb0030","series-title":"Genomic and personalized medicine","first-page":"4","article-title":"Organization, variation and expression of the human genome as a foundation of genomic and personalized medicine","author":"Willard","year":"2009"},{"issue":"5","key":"10.1016\/j.cct.2013.06.012_bb0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuron.2012.05.004","article-title":"Pharmacogenomics and personalized medicine in neuropsychiatry","volume":"74","author":"McMahon","year":"2012","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.cct.2013.06.012_bb0040","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/mp.2012.105","article-title":"Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?","volume":"17","author":"Kapur","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0045","author":"National Institute of Mental Health"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jalz.2010.11.007","article-title":"National estimates of the prevalence of Alzheimer's disease in the United States","volume":"7","author":"Brookmeyer","year":"2011","journal-title":"Alzheimers Dement Jan"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2012.02.001","article-title":"2012 Alzheimer's disease facts and figures","volume":"8","author":"Alzheimer's Association","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5507\/bp.2012.055","article-title":"Epidemiological of and risk factors for Alzheimer's disease: a review","volume":"156","author":"Povova","year":"2012","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Jun"},{"key":"10.1016\/j.cct.2013.06.012_bb0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/humu.22117","article-title":"Locus-specific mutation databases for neurodegenerative brain diseases","volume":"33","author":"Cruts","year":"2012","journal-title":"Hum Mutat"},{"issue":"5","key":"10.1016\/j.cct.2013.06.012_bb0070","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00005072-199409000-00002","article-title":"Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease","volume":"53","author":"Roses","year":"1994","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.cct.2013.06.012_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS\u2013ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0095","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","article-title":"Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer's disease","volume":"45","author":"Price","year":"1999","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1358\/dot.2013.49.3.1937428","article-title":"Florbetapir F 18 for brain imaging of \u03b2-amyloid plaques","volume":"49","author":"Romano","year":"2013","journal-title":"Drugs Today (Barc)"},{"issue":"20","key":"10.1016\/j.cct.2013.06.012_bb0105","doi-asserted-by":"crossref","first-page":"11049","DOI":"10.1073\/pnas.96.20.11049","article-title":"Cellular mechanisms of beta-amyloid production and secretion","volume":"96","author":"Sinha","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cct.2013.06.012_bb0110","series-title":"ISRN, Pharmacology","first-page":"984786","article-title":"Biomarkers in Alzheimer's disease: a review","author":"Chintamaneni","year":"2012"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Disease Neuroimaging Initiative","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/bmm.12.41","article-title":"Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers","volume":"6","author":"Mattsson","year":"2012","journal-title":"Biomark Med"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/bmm.12.42","article-title":"Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease","volume":"6","author":"Fagan","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.cct.2013.06.012_bb0140","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1038\/tp.2013.11","article-title":"Soluble amyloid precursor protein \u03b2 as blood-based biomarker of Alzheimer's disease","volume":"3","author":"Perneczky","year":"2013","journal-title":"Transl Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/bmm.12.48","article-title":"Plasma biomarkers for Alzheimer's disease: much needed but tough to find","volume":"6","author":"Bazenet","year":"2012","journal-title":"Biomark Med"},{"issue":"20","key":"10.1016\/j.cct.2013.06.012_bb0150","article-title":"Fluid biomarkers in Alzheimer's disease - current concepts","volume":"8","author":"Ros\u00e9n","year":"2013","journal-title":"Mol Neurodegener"},{"issue":"12","key":"10.1016\/j.cct.2013.06.012_bb0155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case\u2013control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.cct.2013.06.012_bb0160","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/archneurol.2012.1282","article-title":"Blood-based protein biomarkers for diagnosis of Alzheimer disease. Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group","volume":"69","author":"Doecke","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cct.2013.06.012_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3949\/ccjm.76a.072178","article-title":"Alzheimer disease: time to improve its diagnosis and treatment","volume":"76","author":"Salloway","year":"2009","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2011.12.002","article-title":"Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors","volume":"134","author":"Tayeb","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"6740","key":"10.1016\/j.cct.2013.06.012_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4933-10-18","article-title":"Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets?","volume":"10","author":"Moreth","year":"2013","journal-title":"Immunol Ageing"},{"issue":"7399","key":"10.1016\/j.cct.2013.06.012_bb0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/485426a","article-title":"US government sets out Alzheimer's plan","volume":"485","author":"Wadman","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1756285611404470","article-title":"Disease-modifying treatments for Alzheimer's disease","volume":"4","author":"Galimberti","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"13","key":"10.1016\/j.cct.2013.06.012_bb0200","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1302513","article-title":"Regulatory innovation and drug development for early-stage Alzheimer's disease","volume":"368","author":"Kozauer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.cct.2013.06.012_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/bmb\/lds004","article-title":"The neurobiology of depression","volume":"101","author":"Palazidou","year":"2012","journal-title":"Br Med Bull"},{"key":"10.1016\/j.cct.2013.06.012_bb0220","series-title":"\u201cMental health atlas\u201d. Mental disorders. Depression fact sheet","author":"WHO","year":"2005"},{"issue":"9","key":"10.1016\/j.cct.2013.06.012_bb0225","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archpsyc.1976.01770090041003","article-title":"Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients","volume":"33","author":"Carroll","year":"1976","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-0327(80)90004-X","article-title":"Diagnosis of endogenous depression. Comparison of clinical, research and neuroendocrine criteria","volume":"2","author":"Carroll","year":"1980","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archpsyc.1981.01780260017001","article-title":"A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility","volume":"38","author":"Carroll","year":"1981","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0240","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1176\/ajp.144.10.1253","article-title":"The dexamethasone suppression test: an overview of its current status in psychiatry","volume":"144","author":"American Psychiatric Association","year":"1987","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0245","first-page":"1","article-title":"Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study","author":"Papakostas","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0250","unstructured":"Diagnostics, Ridge. \u201cMDDScore\u2122 Product Brief\u201d: 110. \u201cImproving the diagnosis of major depressive disorder: a new multi-analyte biomarker panel\u201d."},{"issue":"9","key":"10.1016\/j.cct.2013.06.012_bb0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cct.2013.06.012_bb0260","first-page":"5","article-title":"Problems with currently available antidepressants","volume":"51\u20134","author":"Gumnick","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.cct.2013.06.012_bb0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.2000.tb10944.x","article-title":"Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors","volume":"403","author":"Peretti","year":"2000","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.cct.2013.06.012_bb0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1592\/phco.29.7.822","article-title":"Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions","volume":"7","author":"Thomas","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0275","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.cct.2013.06.012_bb0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archpsyc.64.7.783","article-title":"Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression","volume":"64","author":"Hu","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajmg.b.30816","article-title":"SLC6A4 variation and citalopram response","volume":"150B","author":"Mrazek","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"5292","key":"10.1016\/j.cct.2013.06.012_bb0290","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","article-title":"Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region","volume":"274","author":"Lesch","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0295","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1460-9568.2003.02446.x","article-title":"The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit","volume":"17","author":"Lovejoy","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"20\u201321","key":"10.1016\/j.cct.2013.06.012_bb0305","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.lfs.2013.03.009","article-title":"Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression","volume":"92","author":"Poland","year":"2013","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.cct.2013.06.012_bb0310","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1176\/appi.ajp.2007.06111790","article-title":"Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort","volume":"164","author":"Paddock","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.cct.2013.06.012_bb0315","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2007.10.026","article-title":"The FKBP5-gene in depression and treatment response\u2014an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)","volume":"63","author":"Lekman","year":"2008","journal-title":"Cohort Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.cct.2013.06.012_bb0320","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/npp.2008.6","article-title":"Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study","volume":"33","author":"Perlis","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.cct.2013.06.012_bb0325","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1176\/ps.2009.60.11.1446","article-title":"Pharmacogenetics studies in STAR*D: strengths, limitations, and results","volume":"60","author":"Laje","year":"2009","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1503\/jpn.100059","article-title":"Pharmacogenetics of antidepressant response","volume":"36","author":"Porcelli","year":"2011","journal-title":"J Psychiatry Neurosci"},{"issue":"7","key":"10.1016\/j.cct.2013.06.012_bb0335","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.31887\/DCNS.2010.12.1\/dmrazek","article-title":"Psychiatric pharmacogenomic testing in clinical practice","volume":"12","author":"Mrazek","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1092852900020022","article-title":"DNA microarray technology in the clinical environment: the AmpliChip CYP450 Test for CYP2D6 and CYP2C19 genotyping","volume":"14","author":"de Leon","year":"2009","journal-title":"CNS Spectr"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/npp.2008.147","article-title":"Pharmacogenomics: the promise of personalized medicine for CNS disorders","volume":"34","author":"de Leon","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0355","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4161\/epi.7.2.18764","article-title":"Basic concepts of epigenetics: impact of environmental signals on gene expression","volume":"7","author":"Mazzio","year":"2012","journal-title":"Epigenetics"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0360","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/nu5030887","article-title":"Genomic and epigenomic insights into nutrition and brain disorders","volume":"5","author":"Dauncey","year":"2013","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.cct.2013.06.012_bb0365","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4161\/epi.6.8.16793","article-title":"The early life social environment and DNA methylation: DNA methylation mediating the long-term impact of social environments early in life","volume":"6","author":"Szyf","year":"2011","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0370","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrn3393","article-title":"The circadian clock: a framework linking metabolism, epigenetics and neuronal function","volume":"14","author":"Masri","year":"2013","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.cct.2013.06.012_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2042-6410-4-1","article-title":"Sex, stress, and epigenetics: regulation of behavior in animal models of mood disorders","volume":"4","author":"Hodes","year":"2013","journal-title":"Biol Sex Differ"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0380","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tig.2012.12.008","article-title":"Bridging the transgenerational gap with epigenetic memory","volume":"29","author":"Lim","year":"2013","journal-title":"Trends Genet"},{"issue":"8","key":"10.1016\/j.cct.2013.06.012_bb0385","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nn1276","article-title":"Epigenetic programming by maternal behavior","volume":"7","author":"Weaver","year":"2004","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.cct.2013.06.012_bb0390","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nn.2270","article-title":"Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse","volume":"12","author":"McGowan","year":"2009","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.1016\/j.cct.2013.06.012_bb0395","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1734-1140(11)70498-4","article-title":"Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs","volume":"63","author":"Baer-Dubowska","year":"2011","journal-title":"Pharmacol Rep"},{"issue":"4","key":"10.1016\/j.cct.2013.06.012_bb0400","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2009.2","article-title":"Pharmacoepigenetics: its role in interindividual differences in drug response","volume":"85","author":"Gomez","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cct.2013.06.012_bb0405","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neuroimage.2012.09.019","article-title":"Imaging epigenetic regulation by histone deacetylases in the brain using PET\/MRI with 18F-FAHA","volume":"64","author":"Yeh","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.cct.2013.06.012_bb0410","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1038\/tp.2012.99","article-title":"Using a pharmacogenomic algorithm to guide the treatment of depression","volume":"2","author":"Hall-Flavin","year":"2012","journal-title":"Transl Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714413001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714413001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T19:56:39Z","timestamp":1645905399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714413001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1551714413001043"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2013.06.012","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized medicine in Alzheimer's disease and depression","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2013.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}